Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company employing epigenetics – a novel way to control gene expression – to overcome the problem of resistance seen with current oncology treatments. We are focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.

NASDAQ: SNDX
$ 14.68 -0.14 (0.95%)
Day High: 15.18
Day Low:  14.52
Volume:    31,334
12:32 PM ET
08.25.16

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations